Gain detailed insights into the trading activity of Congress members for Icon on our government trades page. Stay updated on how elected officials are investing in ICLR.

Icon - Government Trades

Icon

Icon is a global late-stage contract research organization that provides drug development and clinical trial services to pharmaceutical, biotechnology, and medical-device firms. While the vast majority of its revenue comes from clinical research, Icon also offers ancillary services such as laboratory and imaging capabilities. The company is headquartered in Ireland.

Analyst Color

Earnings

Large Cap

News

Guidance

Health Care

Reiteration

Analyst Ratings

Movers

Trading Ideas

General

ICLR

IQVIA Holdings Inc (NASDAQ:IQV) reported a second adjusted EPS of $2.64, up from $2.43, beating the consensus of $2.57.

IQVIA &#39;Is A Solid Investment&#39; With Strong Competitive Positioning, Analyst Says After Better Than Expected Q2 Earnings

Markets

Growth investors focus on stocks that are seeing above-average financial growth, as this feature helps these securities garner the market&#39;s attention and deliver solid returns. But finding a growth stock that can live up to its true potential can be a tough task.

Icon PLC is an Incredible Growth Stock: 3 Reasons Why

Penny Stocks

Small Cap

Intraday Update

ACVA

ALTI

Amplify YieldShares Oil Hedged MLP Income ETF

AMLX

DELL

DOCN

INDV

LNTH

MATV

MRNA

NICE

NVAX

NVDA

OCUL

QTWO

RELY

RILY

ROOT

SMCI

SNPS

WING

U.S. stocks were higher, with the Nasdaq Composite gaining more 2% on Thursday.

NICE Posts Upbeat Earnings, Joins FTI Consulting, NVIDIA, Moderna And Other Big Stocks Moving Higher On Thursday

Price Target

Pre-Market Outlook

CYBR

DLTR

SCHW

SPWR

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page

Lennox International To Rally 22%? Here Are 10 Top Analyst Forecasts For Tuesday

Long Ideas

Media

PYPL

UBER

On CNBC’s &#34;Halftime Report Final Trades,&#34;  Stephen Weiss  of Short Hills Capital Partners said  Uber Technologies, Inc.

Uber Technologies, Blackstone And A Major Healthcare Company: CNBC&#39;s &#39;Final Trades&#39;

ASTS

BLBD

CANO

PAGP

PGTI

On CNBC’s &#34;Mad Money Lightning Round,&#34; Jim Cramer said  AST SpaceMobile Inc (NASDAQ: ASTS) is an &#34;exciting thing, not a stock.

Jim Cramer Says This Stock Down 25% This Year Is &#39;Not To Be Touched, Because They&#39;re Doing Very Poorly&#39;

Nestle Sponsored representing Registered Shares Series B

NSRGY

TEVA

On CNBC’s &#34;Mad Money Lightning Round,&#34; Jim Cramer recommended selling Marqeta Inc (NASDAQ: MQ) adding that &#34;too many companies doing the same thing as they are, and they’re losing money.&#34;

Cramer Says This Stock Is Losing Money As &#39;Too Many Companies Doing The Same Thing&#39;

PLCE


	Wells Fargo raised the price target on  Lockheed Martin Corporation  (NYSE: LMT) from $400 to $486. Lockheed Martin shares rose 1.3% to $464.10 in pre-market trading.


10 Biggest Price Target Changes For Monday

AMZN

BBBY

COST

INMD

XLRN


	Morgan Stanley cut  Amazon.com, Inc. (NASDAQ: AMZN) price target from $4,300 to $4,100. Amazon shares fell 0.6% to $3,406.00 in pre-market trading.


Biotech

Offerings

ABBV

ADAP

ADMS

AERI

AFIB

AGIO

AKBA

ALBO

ALLO

AMRN

APLS

APYX

BCRX

BLUE

BMRN

BNTX

CERS

CLBS

CLNN

CMRX

CNCE

COLL

CTMX

CYTK

DRNA

DVAX

EDIT

ENDP

FPRX

GKOS

GMTX

GNMK

HALO

HZNP

ICPT

ICUI

IFRX

INSM

IOVA

ITCI

JAZZ

JNCE

KALA

KRTX

KRYS

LMAT

MDWD

MNKD

NKTR

NTLA

NTRA

NTUS

NUVA

NVCR

OFIX

PAND

PBYI

PCRX

PLRX

PRAH

PRTC

PRVB

PTCT

RCEL

RDUS

RHHBY

SELB

SLDB

SRPT

TCON

TNDM

VNDA

VYGR

XENE

XNCR

ZGNX

ZIOP

Here&#39;s a roundup of top developments in the biotech space over the last 24 hours:

Scaling The Peaks

(Biotech Stocks Hitting 52-week Highs Feb. 24)

The Daily Biotech Pulse: Merck Goes Shopping, Decision Day For Sarepta, Pfizer, Moderna Unveil Vaccine Strategies For Coronavirus Variants

Icon PLC

Icon (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ICLR#NASDAQ">ICLR</a>) has outperformed the market over the past 5 years by 1.83% on an annualized basis producing an average annual return of 16.02%. Currently, Icon has a market capitalization of $26.91 billion. 
Buying $100 In ICLR: If an investor had bought $100 of ICLR stock 5 years ago, it would be worth $211.32 today based on a price of $324.91 for ICLR at the time of writing.
<h3>Icon's Performance Over Last 5 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1724180423_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

$100 Invested In Icon 5 Years Ago Would Be Worth This Much Today

Nigel will be based in ICON&#39;s Dublin office and will join ICON early in quarter four this year.

Management

ICON Appoints Nigel Clerkin As Its New CFO

Icon (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ICLR#NASDAQ">ICLR</a>) has outperformed the market over the past 10 years by 9.49% on an annualized basis producing an average annual return of 19.93%. Currently, Icon has a market capitalization of $25.88 billion. 
Buying $100 In ICLR: If an investor had bought $100 of ICLR stock 10 years ago, it would be worth $613.16 today based on a price of $312.53 for ICLR at the time of writing.
<h3>Icon's Performance Over Last 10 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1722978017_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Here's How Much You Would Have Made Owning Icon Stock In The Last 10 Years

Barclays analyst Luke Sergott maintains Icon (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ICLR#NASDAQ">ICLR</a>) with a Overweight and lowers the price target from $355 to $350.

Barclays Maintains Overweight on Icon, Lowers Price Target to $350

Truist Securities analyst Jailendra Singh maintains Icon (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ICLR#NASDAQ">ICLR</a>) with a Buy and raises the price target from $367 to $383.

Truist Securities Maintains Buy on Icon, Raises Price Target to $383

WIIM

ICON Plc shares are trading lower after the company reported worse-than-expected Q2 revenue.

Icon (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ICLR#NASDAQ">ICLR</a>) reported quarterly earnings of $3.75 per share which beat the analyst consensus estimate of $3.68 by 1.9 percent. The company reported quarterly sales of $2.12 billion which missed the analyst consensus estimate of $2.14 billion by 0.95 percent. This is a 4.95 percent increase over sales of $2.02 billion the same period last year.

Earnings Beats

Earnings Misses

Icon Q2 2024 Adj EPS $3.75 Beats $3.68 Estimate, Sales $2.12B Miss $2.14B Estimate

Icon (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ICLR#NASDAQ">ICLR</a>) has outperformed the market over the past 15 years by 7.5% on an annualized basis producing an average annual return of 19.57%. Currently, Icon has a market capitalization of $27.50 billion. 
Buying $100 In ICLR: If an investor had bought $100 of ICLR stock 15 years ago, it would be worth $1,480.44 today based on a price of $332.23 for ICLR at the time of writing.
<h3>Icon's Performance Over Last 15 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1721831418_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Here's How Much $100 Invested In Icon 15 Years Ago Would Be Worth Today

IQVIA Holdings Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IQV#NASDAQ">IQV</a>) reported a second adjusted EPS of $2.64, up from $2.43, beating the <a target="_blank" href="https://www.benzinga.com/calendars/earnings" rel="noreferrer noopener">consensus of $2.57</a>.
Provider of advanced analytics reported sales of $3.81 billion, beating the <a target="_blank" href="https://www.benzinga.com/pressreleases/24/07/b39879394/iqvia-reports-second-quarter-2024-results" rel="noreferrer noopener">consensus of $3.79 billion</a>.
Sales increased 2.3% on a reported basis and 3.5% at constant currency compared to the second quarter of 2023.
Technology &amp; Analytics Solutions (TAS) revenue of $1.5 billion increased 2.7% on a reported basis and 3.8% at constant currency.
Research &amp; Development Solutions (R&amp;DS) revenue reached $2.15 billion, increasing 2.4% on a reported basis and 3.3% at constant currency.
Excluding the impact of pass-throughs, R&amp;DS revenue grew 3.5% on a reported basis.
Contract Sales &amp; Medical Solutions revenue of $172 million decreased 2.3% on a reported basis and increased 2.8% at constant currency.
As of June 30, 2024, R&amp;DS contracted backlog, including reimbursed expenses, was $30.6 billion, growing 7.7% year-over-year and 8.1% at constant currency.
The company expects approximately $7.8 billion of this backlog to convert to revenue in the next twelve months. The second-quarter book-to-bill ratio was 1.27x.
&#8220;IQVIA delivered second-quarter results at the high-end of our guidance, driven mainly by better-than-expected TAS performance,&#8221; stated Ari Bousbib, chairman and CEO of IQVIA.
Guidance: IQVIA forecasts 2024 revenues of $15.43 billion—$15.53 billion, compared to prior guidance of $15.33 billion—$15.58 billion and a consensus of $15.46 billion.
IQVIA expects 2024 adjusted EPS of $11.10-$11.30 compared to prior guidance of $10.95-$11.25 and consensus of $11.08.
The provider of clinical research services expects 2024 adjusted EBITDA of $3.71 billion—$3.77 billion, versus prior guidance of $3.7 billion—$3.8 billion.
William Blair writes that IQVIA has underperformed so far in 2024 due to skepticism around the timing and pace of recovery in its TAS business.
While R&amp;DS sales and bookings came in slightly short of William Blair&#8217;s expectations, overall, a 1.27 times book-to-bill ratio is still solid, and the analyst is encouraged by management&#8217;s commentary that forward-looking indicators, such as RFP flow and qualified pipeline, remain healthy.
Overall, the analyst notes that IQVIA&#8217;s strong competitive positioning and healthy R&amp;DS business make the company a solid investment, especially given its attractive valuation (it currently trades at 18.0 times 2025EPS, roughly a turn below close peer ICON Plc (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/iclr#NASDAQ">ICLR</a>)). William Blair <a target="_blank" href="https://www.benzinga.com/quote/IQV/analyst-ratings" rel="noreferrer noopener">reiterates an Outperform rating</a>.
Price Action: IQV stock is up 5.88% at $237.77&nbsp;at the last check on Monday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/general/biotech/24/07/39884070/fatty-liver-focused-hepion-pharmaceuticals-agrees-to-merge-with-israel-based-parkinsons-disease-d" target="_blank" rel="noreferrer noopener">Fatty-Liver Focused Hepion Pharmaceuticals Agrees To Merge With Israel-Based Parkinson&#8217;s Disease Drug Developer</a></li>
</ul>

IQVIA 'Is A Solid Investment' With Strong Competitive Positioning, Analyst Says After Better Than Expected Q2 Earnings

Icon (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ICLR#NASDAQ">ICLR</a>) has outperformed the market over the past 15 years by 6.54% on an annualized basis producing an average annual return of 19.38%. Currently, Icon has a market capitalization of $26.56 billion. 
Buying $100 In ICLR: If an investor had bought $100 of ICLR stock 15 years ago, it would be worth $1,462.72 today based on a price of $320.92 for ICLR at the time of writing.
<h3>Icon's Performance Over Last 15 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1720470615_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Here's How Much You Would Have Made Owning Icon Stock In The Last 15 Years

Baird analyst Eric Coldwell maintains Icon (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ICLR#NASDAQ">ICLR</a>) with a Outperform and raises the price target from $367 to $376.

Baird Maintains Outperform on Icon, Raises Price Target to $376

Icon (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ICLR#NASDAQ">ICLR</a>) has outperformed the market over the past 15 years by 6.88% on an annualized basis producing an average annual return of 19.66%. Currently, Icon has a market capitalization of $26.32 billion. 
Buying $100 In ICLR: If an investor had bought $100 of ICLR stock 15 years ago, it would be worth $1,425.55 today based on a price of $317.92 for ICLR at the time of writing.
<h3>Icon's Performance Over Last 15 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1718395222_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

$100 Invested In This Stock 15 Years Ago Would Be Worth $1,400 Today

Growth investors focus on stocks that are seeing above-average financial growth, as this feature helps these securities garner the market&#39;s attention and deliver solid returns. But finding a growth stock that can live up to its true potential can be a tough task.
By their very nature, these stocks carry above-average risk and volatility. Moreover, if a company&#39;s growth story is over or nearing its end, betting on it could lead to significant loss.
However, it&#39;s pretty easy to find cutting-edge growth stocks with the help of the Zacks Growth Style Score (part of the Zacks Style Scores system), which looks beyond the traditional growth attributes to analyze a company&#39;s real growth prospects.
Our proprietary system currently recommends Icon PLC (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/iclr#NASDAQ">ICLR</a>) as one such stock. This company not only has a favorable Growth Score, but also carries a top Zacks Rank.
Studies have shown that stocks with the best growth features consistently outperform the market. And for stocks that have a combination of a Growth Score of A or B and a Zacks Rank #1 (Strong Buy) or 2 (Buy), returns are even better.
While there are numerous reasons why the stock of this contract research organization is a great growth pick right now, we have highlighted three of the most important factors below:
Earnings Growth
Earnings growth is arguably the most important factor, as stocks exhibiting exceptionally surging profit levels tend to attract the attention of most investors. For growth investors, double-digit earnings growth is highly preferable, as it is often perceived as an indication of strong prospects (and stock price gains) for the company under consideration.
While the historical EPS growth rate for Icon PLC is 18.1%, investors should actually focus on the projected growth. The company&#39;s EPS is expected to grow 17.8% this year, crushing the industry average, which calls for EPS growth of 17.7%.
Cash Flow Growth
While cash is the lifeblood of any business, higher-than-average cash flow growth is more important and beneficial for growth-oriented companies than for mature companies. That&#39;s because, growth in cash flow enables these companies to expand their businesses without depending on expensive outside funds.
Right now, year-over-year cash flow growth for Icon PLC is 8.2%, which is higher than many of its peers. In fact, the rate compares to the industry average of -13.8%.
While investors should actually consider the current cash flow growth, it&#39;s worth taking a look at the historical rate too for putting the current reading into proper perspective. The company&#39;s annualized cash flow growth rate has been 31.4% over the past 3-5 years versus the industry average of 13%.
Promising Earnings Estimate Revisions
Superiority of a stock in terms of the metrics outlined above can be further validated by looking at the trend in earnings estimate revisions. A positive trend is of course favorable here. Empirical research shows that there is a strong correlation between trends in earnings estimate revisions and near-term stock price movements.
The current-year earnings estimates for Icon PLC have been revising upward. The Zacks Consensus Estimate for the current year has surged 0.7% over the past month.
Bottom Line
While the overall earnings estimate revisions have made Icon PLC a Zacks Rank #2 stock, it has earned itself a Growth Score of B based on a number of factors, including the ones discussed above.
This combination positions Icon PLC well for outperformance, so growth investors may want to bet on it.
<a href="https://www.zacks.com/stock/news/2284239/icon-plc-iclr-is-an-incredible-growth-stock-3-reasons-why?cid=CS-BENZ-FT-tale_of_the_tape|yseop_template_11_growth-2284239">To read this article on Zacks.com click here.</a>

Goldman Sachs analyst Matthew Sykes initiates coverage on Icon (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ICLR#NASDAQ">ICLR</a>) with a Buy rating and announces Price Target of $370.

Initiation

Goldman Sachs Initiates Coverage On Icon with Buy Rating, Announces Price Target of $370

TD Cowen analyst Charles Rhyee maintains Icon (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ICLR#NASDAQ">ICLR</a>) with a Buy and raises the price target from $349 to $373.

TD Cowen Maintains Buy on Icon, Raises Price Target to $373

Baird analyst Eric Coldwell maintains Icon (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ICLR#NASDAQ">ICLR</a>) with a Outperform and raises the price target from $363 to $367.

Baird Maintains Outperform on Icon, Raises Price Target to $367

Icon (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ICLR#NASDAQ">ICLR</a>) has outperformed the market over the past 10 years by 11.78% on an annualized basis producing an average annual return of 22.28%. Currently, Icon has a market capitalization of $26.91 billion. 
Buying $1000 In ICLR: If an investor had bought $1000 of ICLR stock 10 years ago, it would be worth $7,562.40 today based on a price of $325.41 for ICLR at the time of writing.
<h3>Icon's Performance Over Last 10 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1717084833_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Here's How Much $1000 Invested In Icon 10 Years Ago Would Be Worth Today


Kevin HernHouse (R-OK)	$1K - $15K	stock	Sale	Feb 14, 2023	Jan 31, 2023	House
Kevin HernHouse (R-OK)	$15K - $50K	stock	Purchase	Oct 07, 2021	Sep 02, 2021	House

Get Our Top Trade Ideas Delivered Daily - 65% Off Now'

Get Our Top Trade Ideas Delivered Daily - 65% Off Now'

Government Trades

Icon PLC

top performing ICLR trades